{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:39:55Z","timestamp":1761946795239},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/nrneph.2016.138","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T06:06:38Z","timestamp":1474869998000},"page":"653-654","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A pharmacological chaperone on the horizon"],"prefix":"10.1038","volume":"12","author":[{"given":"Martina","family":"Gaggl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"BFnrneph2016138_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","volume":"146","author":"JT Clarke","year":"2007","unstructured":"Clarke, J. T. Narrative review: Fabry disease. Ann. Intern. Med. 146, 425\u2013433 (2007).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2016138_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ymgme.2008.07.002","volume":"95","author":"A Mehta","year":"2008","unstructured":"Mehta, A.  et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol. Genet. Metab. 95, 114\u2013115 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneph2016138_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/joim.12089","volume":"274","author":"AB Mehta","year":"2013","unstructured":"Mehta, A. B. Fabry disease: is there a role for enzyme replacement therapy? J. Intern. Med. 274, 329\u2013330 (2013).","journal-title":"J. Intern. Med."},{"key":"BFnrneph2016138_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40265-016-0607-y","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham, A. Migalastat: first global approval. Drugs 76, 1147\u20131152 (2016).","journal-title":"Drugs"},{"key":"BFnrneph2016138_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1750-1172-7-91","volume":"7","author":"DP Germain","year":"2012","unstructured":"Germain, D. P.  et al. Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J. Rare Dis. 7, 91 (2012).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFnrneph2016138_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P.  et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545\u2013555 (2016).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016138_CR7","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.ymgme.2014.12.118","volume":"114","author":"D Hughes","year":"2015","unstructured":"Hughes, D.  et al. Long-term efficacy and safety of migalastat compared to enzyme replacement therapy in Fabry disease: phase 3 study results. Mol. Genet. Metab. 114, S57 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrneph2016138_CR8","doi-asserted-by":"publisher","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","volume":"10","author":"DG Warnock","year":"2015","unstructured":"Warnock, D. G.  et al. Oral migalastat HCl leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase A in Fabry patients when co-administered with infused agalsidase. PLoS ONE 10, e0134341 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrneph2016138_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders, M.  et al. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J. Am. Soc. Nephrol. 27, 256\u2013264 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016138_CR10","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1039\/C6CC01564F","volume":"52","author":"EM Sanchez-Fernandez","year":"2016","unstructured":"Sanchez-Fernandez, E. M., Garcia Fernandez, J. M. & Mellet, C. O. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem. Commun. 52, 5497\u20135515 (2016).","journal-title":"Chem. Commun."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:48:09Z","timestamp":1684471689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2016.138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFnrneph2016138"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2016.138","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]},"assertion":[{"value":"26 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.G. has received a travel grant from Shire HGT. G.S.-P. has received funding from Amicus, Sanofi-Genzyme, and Shire HGT. G.S.-P. and M.G. are investigators of the ATTRACT trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}